Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Optimized Background Therapy (OBT)
Optimized Background Therapy · 1 trial · 1 indication
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \[log10 copies/mL\]). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and baseline visits.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Optimized Background Therapy (OBT) | DRUG | OBT (3-6 drugs based on treatment history and resistance testing) |
| maraviroc (UK-427,857) | DRUG | maraviroc (UK-427,857) 150 mg taken once daily |
Inclusion Criteria: * Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities) * HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL * Stable pre-study antiretroviral regimen, or on no antiretroviral agents, for at least 4 weeks * Documented ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Optimized Background Therapy (OBT) is used in the treatment of HIV Infections. In clinical research, OBT refers to a customized combination of antiretroviral drugs selected for an individual patient based on their prior treatment history and resistance profile, serving as the background regimen to which an investigational agent is added.
GSK plc (ticker: GSK) is the developer associated with Optimized Background Therapy (OBT). The company sponsored a Phase 2 trial evaluating OBT in combination with maraviroc (UK-427,857) versus OBT alone in antiretroviral-experienced, non-CCR5-tropic HIV-1 infected subjects.
Optimized Background Therapy (OBT) has been studied in a Phase 2 clinical trial. It is an investigational approach and is not an approved standalone product. The Phase 2 study has been completed, and no active trials of OBT are currently listed.
Optimized Background Therapy (OBT) was evaluated in the completed Phase 2 trial NCT00098748, titled "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects." The trial enrolled 190 participants across the United States, Australia, Belgium, Canada, Germany, Netherlands, Spain, Switzerland, and the United Kingdom.
Yes, Optimized Background Therapy (OBT) is the same as Optimized Background Therapy. OBT is simply the abbreviated form of the full term. Both refer to the same concept used in HIV treatment and clinical trial design.